{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-004824","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2024-01-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.862902+00:00","generated_at":"2026-06-06T22:41:30.945535+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"PepGen appoints Mary Beth DeLena as General Counsel and Secretary","bullets":["Mary Beth DeLena joins PepGen as General Counsel and Secretary, effective January 17, 2024.","She brings over 20 years of legal experience, most recently 15 years at Alnylam Pharmaceuticals as SVP, Deputy General Counsel.","At Alnylam, she advised on strategic collaborations, licensing, and capital-raising through the company's transition to commercial stage.","PepGen CEO cites her expertise in commercial, regulatory, and policy matters as key to advancing oligonucleotide therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-004824","json":"https://secwatch.observer/filing/0000950170-24-004824.json","markdown":"https://secwatch.observer/filing/0000950170-24-004824.md","text":"https://secwatch.observer/filing/0000950170-24-004824.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024004824/0000950170-24-004824-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024004824/pepg-20240117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T22:41:30.945535+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}